metastatic pancreatic ductal adenocarcinoma

Frontline Liposomal Irinotecan/NALIRIFOX Produces OS Benefits in Metastatic Pancreatic Ductal Adenocarcinoma

First-line treatment with the combination of liposomal irinotecan (Onivyde) plus 5-fluorouracil (5-FU), leucovorin and oxaliplatin (NALIRIFOX) produced clinically significant and statistically significant improvement in overall survival (OS) and progression-free survival (PFS) vs nab-paclitaxel (Abraxane) plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), according to the results of the phase 3 study NAPOLI 3 […]

Scroll to top